JPRN-UMIN000027887已完成2 期
Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer - TRIUMPH study
ational Cancer Center Hospital East0 个研究点目标入组 30 人开始时间: 2017年7月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Has a known history of bone marrow transplantation or organ transplantation 2)Has a positive result on the serum pregnancy test 3)Is judged by the investigator to be inappropriate for study participation for any reason.
研究者
相似试验
进行中（未招募）
不适用
Study to assess the efficacy and the safetyof front-line therapy (Fludarabine, Cyclophosphamide and Ofatumumab) in young (=65 yrs) patientswith Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaEUCTR2011-005329-27-ITG.I.M.EM.A.Gruppo Italiano Malattie Ematologiche dell'Adulto
招募中
2 期
A multicenter phase II study to evaluate the efficacy and safety of fixed-duration sequential treatment combined with novel agents and autologous stem cell transplantation for newly diagnosed elderly multiple myeloma. -JSCT EMM21Multiple myelomaJPRN-jRCTs071210084Kikushige Yoshikane75
招募中
1 期
Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.BRAF V600E mutated and microsatellite stable (MSS) advanced colorectal cancer (aCRC) initially resectable or potentially resectableMedDRA version: 21.0Level: PTClassification code: 10052360Term: Colorectal adenocarcinoma Class: 100000004864CTIS2022-502413-29-00Asociacion Grupo Tratamiento De Tumores Digestivos70
进行中（未招募）
1 期
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years oldMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10029261Term: Neuroblastoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005617-14-DKovartis Pharma AG230
进行中（未招募）
1 期
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)EUCTR2021-005617-14-CZovartis Pharma AG230